1.
Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
by Fleischmann, Roy
Clinical rheumatology, 2021, Vol.40 (11), p.4369-4372
2.
Interleukin-6 inhibition for rheumatoid arthritis
by Fleischmann, Roy
The Lancet (British edition), 2017, Vol.389 (10075), p.1168-1170
3.
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
by van Vollenhoven, Ronald F
Annals of the rheumatic diseases, 2013, Vol.72 (9), p.1496-1502
4.
Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
by Burmester, Gerd-Rűdiger
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1037-1044
5.
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoi...
by Kavanaugh, Arthur
Annals of the rheumatic diseases, 2013, Vol.72 (1), p.64-71
6.
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
by Schiff, Michael
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.86-94
7.
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised con...
by Smolen, Josef S, Prof
The Lancet (British edition), 2014, Vol.383 (9914), p.321-332
8.
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
by Charles-Schoeman, Christina Christina
Annals of the rheumatic diseases, 2015, Vol.75 (7), p.1293-1301
9.
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results fro...
by Sokolove, Jeremy Jeremy
Annals of the rheumatic diseases, 2015, Vol.75 (4), p.709-714
10.
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
by Smolen, Josef S, Prof
The Lancet (British edition), 2016, Vol.388 (10061), p.2763-2774
11.
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the r...
by Huizinga, Tom W J
Annals of the rheumatic diseases, 2014, Vol.73 (9), p.1626-1634
12.
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
by Genovese, Mark C
Annals of the rheumatic diseases, 2014, Vol.73 (9), p.1607-1615
13.
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
by Genovese, Mark C
Annals of the rheumatic diseases, 2013, Vol.72 (9), p.1461-1468
14.
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
by Fleischmann, Roy
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1132-1137
15.
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoi...
by Kay, Jonathan
Annals of the rheumatic diseases, 2015, Vol.74 (3), p.538-546
16.
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
by Stohl, William
Annals of the rheumatic diseases, 2012, Vol.71 (8), p.1289-1296
17.
Response to: ‘Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a...
by Fleischmann, Roy
Annals of the rheumatic diseases, 2015, Vol.74 (1), p.e6-e6
18.
Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?
by Fleischmann, Roy
Annals of the rheumatic diseases, 2014, Vol.73 (9), p.e54-e54
19.
Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation
by Kirkham, Bruce W
Annals of the rheumatic diseases, 2014, Vol.73 (1), p.161-169
20.
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the...
by van der Heijde, Désirée
Clinical rheumatology, 2018, Vol.37 (9), p.2381-2390
